Active-ingredient Dossier
Rivaroxaban
Active-ingredient Dossier for Rivaroxaban (direct factor xa inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: RELABAN
- Brand: Rivaroxaban APOTEX
- Brand: XARELTO
- Brand: RIVAXIB
- Brand: ARX-RIVAROXABAN
- Brand: IXAROLA
- Therapeutic area: Cardiology
What is
Rivaroxaban Rivaroxaban is a direct factor Xa inhibitor.
Australian brands containing
Rivaroxaban — RELABAN — Rivaroxaban APOTEX — XARELTO — RIVAXIB — APO-RIVAROXABAN — ARX-RIVAROXABAN — IXAROLA — RIVARELTO — RIVAROXABAN — RIVAROXABAN DR.REDDY'S — RIVAROXABAN SANDOZ — RIVAROXABAN-TEVA
Therapeutic areas
Rivaroxaban is registered in neurology (38 brands) and cardiology (1 brand).
Sponsor landscape
Rivaroxaban is marketed by multiple sponsors including Torrent, Micro Labs, Alembic Pharmaceuticals, Dr Reddys Laboratories, Arrotex Pharmaceuticals, and Nova Pharmaceuticals.
PBS and regulatory activity
Three brands containing rivaroxaban have PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2024–25 financial year, government expenditure on rivaroxaban reached $111,816,509 across 2,453,795 scripts. The latest PBAC outcome was recorded on 1 November 2024, with three brands having PBAC outcomes on record. The latest AusPAR was issued on 27 June 2013, with one brand having an AusPAR on record.